Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Textual)

v3.8.0.1
Commitments and Contingencies (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 13, 2017
Jun. 08, 2017
Aug. 04, 2016
Jun. 15, 2012
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Commitments and Contingencies (Textual)              
Rent for office   $ 7,529          
Incurred expenses         $ 17,699,503 $ 17,786,655 $ 13,501,895
Cost of lease agreement         312,660    
Accounts payable and accrued expenses         $ 4,625,088 4,194,874  
Lease agreements, description         The lease expires September 6, 2024 with an annual rental rate of $312,660 per year through June 6, 2021 and an annual rate of $341,610 for the remaining period.    
Lines of credit         $ 390,825    
Deposit         390,940    
Fred Hutchinson Cancer Research Center [Member]              
Commitments and Contingencies (Textual)              
Milestones Payments       $ 1,000,000      
Description of royalty payment       Royalty payments of 2% of net sales will be due to FHCRC.      
Incurred expenses         45,000    
Medpace Inc [Member]              
Commitments and Contingencies (Textual)              
Incurred expenses         2,800,000 2,600,000  
Total project estimated to cost         7,200,000    
Oak Ridge National Laboratory [Member]              
Commitments and Contingencies (Textual)              
Purchase of materials $ 2,000,000       600,000 1,000,000 800,000
George Clinical Services [Member]              
Commitments and Contingencies (Textual)              
Project estimated cost     $ 4,600,000   700,000 100,000  
Goodwin Biotechnology Inc [Member]              
Commitments and Contingencies (Textual)              
Project remaining cost         1,800,000    
Incurred expenses         4,200,000 $ 700,000 $ 1,400,000
Product Development and Patent License Agreement [Member] | AbbVie Biotherapeutics Corp. [Member]              
Commitments and Contingencies (Textual)              
License fee payment         $ 3,000,000    
Description of royalty payment         The Company shall pay to AbbVie Biotherapeutics Corp. on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.    
Royalty of net sales percentage         12.00%    
First commercial sale period         12 years 6 months    
Accounts payable and accrued expenses         $ 750,000